EXEL Up 7% pre-market on Cometriq approval in Europe. Although down overall the past few weeks this one has held up well recently against the overall biotech selling.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.